Clinical Research Directory

Inclusion Criteria: * Patients of both sexes with psoriasis vulgaris and Psoriatic arthritis. * Active PsA with three or more tender and swollen joints and met the CASPAR, despite previous treatment with NSAIDs, DMARDs or anti-TNFs Exclusion Criteria: * Previously received biologic immunomodulating agents, except for those targeting TNF * Previously been treated with three or more different TNF inhibitors * Active, ongoing inflammatory diseases other than PsA * Active TB (patients with latent TB had to commence treatment for latent TB before study entry) * A history of hepatitis B or C, human immunodeficiency virus, or any active systemic infection within the 2 weeks before baseline * History of ongoing, chronic or recurrent infections, or evidence of active TB infection * History of malignancy within the past 5 years (except for basal cell carcinoma or actinic keratosis that has been treated with no evidence of recurrence in the past 3 months, in situ cervical cancer or non-invasive malignant colon polyps that had been removed) * Underlying metabolic, hematological, renal, hepatic, pulmonary, neurological, endocrine, cardiac, infectious or gastrointestinal conditions which, in the opinion of the investigator, immunocomprimised the patient and/or placed the patient at unacceptable risk for participation * Pregnant or nursing (lactating) women and women of child-bearing potential unwilling to use effective contraception during the study and for 16 weeks after stopping treatment